Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Equities
US5288721047
Biotechnology & Medical Research
Sales 2024 * | 25.81M 35.28M | Sales 2025 * | 77.52M 106M | Capitalization | 389M 532M |
---|---|---|---|---|---|
Net income 2024 * | -199M -272M | Net income 2025 * | -193M -264M | EV / Sales 2024 * | 15.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.02 x |
P/E ratio 2024 * |
-2.22
x | P/E ratio 2025 * |
-2.49
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.99% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |